Type One Energy Issues First Realistic, Unified Fusion Power Plant Design Basis
27.3.2025 16:28:00 CET | Business Wire | Press release
Type One Energy announced today publication of the world’s first comprehensive, self-consistent, and robust physics basis, with conservative design margins, for a practical fusion pilot power plant. This physics basis is presented in a series of seven peer-reviewed scientific papers in a special issue of the prestigious Journal of Plasma Physics (JPP). They serve as the foundation for the company’s first Infinity Two stellarator fusion power plant project, which Type One Energy is developing for the Tennessee Valley Authority (TVA) utility in the U.S.
The Infinity Two fusion pilot power plant physics design basis realistically considers, for the first time, the complex relationship between competing requirements for plasma performance, power plant startup, construction logistics, reliability, and economics utilizing actual power plant operating experience. This Infinity Two baseline physics solution makes use of the inherently favorable operating characteristics of highly optimized stellarator fusion technology using modular superconducting magnets, as was so successfully proven on the W7-X science machine in Germany.
“Why are we the first private fusion company with an agreement to develop a potential fusion power plant project for an energy utility? Because we have a design anchored in reality,” said Christofer Mowry, CEO of Type One Energy. “The physics basis for Infinity Two is grounded in the knowledge of what is required for application to, and performance in, the demanding environment of reliable electrical generation for the power grid. We have an organization that understands this isn’t about designing a science project.”
Led by Chris Hegna, widely recognized as a leading theorist in modern stellarators, Type One Energy performed high-fidelity computational plasma physics analyses to substantially reduce the risk of meeting Infinity Two power plant functional and performance requirements. This unique and transformational achievement is the result of a global development program led by the Type One Energy plasma physics and stellarator engineering organization, with significant contributions from a broad coalition of scientists from national laboratories and universities around the world. The company made use of a spectrum of high-performance computing facilities, including access to the highest-performance U.S. Department of Energy supercomputers such as the exascale Frontier machine at Oak Ridge National Laboratory (ORNL), to perform its stellarator physics simulations.
“We committed to this ambitious fusion commercialization milestone two years ago and today we delivered,” said John Canik, Chief Science and Engineering Officer for Type One Energy. “The team was able to efficiently develop deep plasma physics insights to inform the design of our Infinity Two stellarator, by taking advantage of our access to high performance computing resources. This enabled the Type One Energy team to demonstrate a realistic, integrated stellarator design that moves far beyond conventional thinking and concepts derived from more limited modeling capabilities.”
The consistent and robust physics solution for Infinity Two results in a deuterium-tritium (D-T) fueled, burning plasma stellarator with 800 MW of fusion power and delivers a nominal 350 MWe to the power grid. It is characterized by fusion plasma with resilient and stable behavior across a broad range of operating conditions, very low heat loss due to turbulent transport, as well as tolerable direct energy losses to the stellarator first wall. The Infinity Two stellarator has sufficient room for both adequately sized island divertors to exhaust helium ash and a blanket which provides appropriate shielding and tritium breeding. Type One Energy has high confidence that this essential physics solution provides a good baseline stellarator configuration for the Infinity Two fusion pilot power plant.
“The articles in this issue [of JPP] represent an important step towards a fusion reactor based on the stellarator concept. Thanks to decades of experiments and theoretical research, much of the latter published in JPP, it has become possible to lay out the physics basis for a stellarator power plant in considerable detail,” said Per Helander, head of Stellarator Theory Division at the Max Planck Institute for Plasma Physics. “JPP is very happy to publish this series of papers from Type One Energy, where this has been accomplished in a way that sets new standards for the fidelity and confidence level in this context.”
Important to successful fusion power plant commercialization, this stellarator configuration has enabled Type One Energy to architect a maintenance solution which supports good power plant Capacity Factors (CF) and associated Levelized Cost of Electricity (LCOE). It also supports favorable regulatory requirements for component manufacturing and power plant construction methods essential to achieving a reasonable Over-Night Cost (ONC) for Infinity Two.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250327324853/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom